ResMed initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of ResMed (RMD) with a Neutral rating and $252 price target While there’s a lot to like about the ResMed ...
3 ASX 200 healthcare stocks with 'strong return potential' in 2025
Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to outperform in 2025. Here’s what you need to know.